Abstract
Purpose
The study aimed to investigate the clinical characteristics and prognostic factors of stage IC ovarian clear cell carcinoma (OCCC).
Methods
The Surveillance, Epidemiology, and End Results (SEER) database was accessed for medical records of patients with stage IC OCCC from 1992 to 2016. The clinical and prognostic features of stage IC OCCC from several therapeutic perspectives were identified with Kaplan–Meier method and Cox proportional hazards model.
Results
Totally, 1079 patients were enrolled for the analysis. The median age was 55 (range 24–91) years. 850 (78.8%) patients were treated with chemotherapy, 877 (81.3%) received lymph node (LN) dissection, and 20 (1.9%) underwent radiotherapy. LN dissection (P = 0.501) and chemotherapy (P = 0.130) did not significantly impact cancer-specific survival (CSS). Among patients younger than 45 years, 23 received fertility-sparing surgery (FSS). No significant difference in CSS was observed between the FSS and non-FSS group (P = 0.523). Bilateral tumor (P < 0.001) and larger tumor size (P = 0.010) were significantly and independently associated with poor CSS. Older age (P = 0.001), bilateral tumor (P < 0.001), and larger tumor size (P = 0.005) were significantly and independently associated with poor overall survival (OS), while LN dissection (P = 0.005) was significantly and independently associated with better OS. Significant differences in CSS (P = 0.005) and OS (P < 0.001) were observed between the low- and high-risk groups, which were divided by median risk score.
Conclusion
LN dissection and chemotherapy did not significantly impact CSS, while LN dissection was an independent prognostic factor for OS. Convincing evidence from clinical trials with a large number of patients are further required to develop treatment guidelines.
Similar content being viewed by others
References
Serov SFSR, Sobin LH (1973) International histologic classification of tumors. World Health Organization, Geneva
Machida H, Matsuo K, Yamagami W, Ebina Y, Kobayashi Y, Tabata T et al (2019) Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: a JSGO-JSOG joint study. Gynecol Oncol 153:589–596
Anglesio MS, Bashashati A, Wang YK, Senz J, Ha G, Yang W et al (2015) Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol 236:201–209
Melamed A, Manning-Geist B, Bregar AJ, Diver EJ, Goodman A, Del Carmen MG et al (2017) Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecol Oncol 147:250–256
Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ et al (2017) An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: an NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol 147:243–249
Suzuki K, Takakura S, Saito M, Morikawa A, Suzuki J, Takahashi K et al (2014) Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. Int J Gynecol Cancer 24:1181–1189
Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM et al (2016) Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14:1134–1163
Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C et al (2013) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):24–32
Prat J (2014) Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124:1–5
Surveillance, Epidemiology, and End Results (SEER) Program:Incidence-SEER 18 Regs Custom Data(with additional treatment fields), Nov 2018 Sub (1975–2016 varying) National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission. https://seer.cancer.gov/
Nasioudis D, Mastroyannis SA, Albright BB, Haggerty AF, Ko EM, Latif NA (2018) Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: patterns of use and outcomes. Gynecol Oncol 150:14–18
Takada T, Iwase H, Iitsuka C, Nomura H, Sakamoto K, Omatsu K et al (2012) Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients. Int J Gynecol Cancer 22:573–578
Bogani G, Ditto A, Lopez S, Bertolina F, Murgia F, Pinelli C et al (2020) Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: a systematic review and meta-analysis. Gynecol Oncol 157(1):293–298
Shimizu D, Sato N, Sato T, Makino K, Kito M, Shirasawa H et al (2015) Impact of adjuvant chemotherapy for stage I ovarian carcinoma with intraoperative tumor capsule rupture. J Obstet Gynaecol Res 41:432–439
Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S et al (2009) The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study. Int J Gynecol Cancer 19:1353–1357
Yamazaki H, Todo Y, Shimada C, Takeshita S, Minobe S, Okamoto K et al (2018) Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma. J Gynecol Oncol 29:e19
Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H et al (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94:1369–1374
Park JY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH (2016) Outcomes of fertility-sparing surgery among young women with FIGO stage I clear cell carcinoma of the ovary. Int J Gynaecol Obstet 134:49–52
Yoshihara M, Kajiyama H, Tamauchi S, Suzuki S, Takahashi K, Matsui S et al (2019) Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis. J Gynecol Oncol 30:e102
Hogen L, Thomas G, Bernardini M, Bassiouny D, Brar H, Gien LT et al (2016) The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma. Gynecol Oncol 143:258–263
Ditto A, Martinelli F, Reato C, Kusamura S, Solima E, Fontanelli R et al (2012) Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study. Ann Surg Oncol 19:3849–3855
Kuroda T, Kohno T (2020) Precision medicine for ovarian clear cell carcinoma based on gene alterations. Int J Clin Oncol 25:419–424
Funding
None.
Author information
Authors and Affiliations
Contributions
Qian Chen: Data Collection, Manuscript writing/editing. Shu Wang: Project development, Manuscript editing. Jing-He Lang: Data analysis, Manuscript editing.
Corresponding authors
Ethics declarations
Conflicts of interest
The authors declare that they have no conflict of interest.
Consent
Written informed consents were exempt since the data we used were obtained from the publicly available SEER database.
Ethics approval
All procedures performed in these studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was deemed exempt by the Ethics Committee of Peking Union Medical College Hospital, Beijing, China, since the data we used were obtained from the publicly available SEER database.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Chen, Q., Wang, S. & Lang, JH. Clinical characteristics and prognostic factors of stage IC ovarian clear cell carcinoma: a Surveillance, Epidemiology, and End Results (SEER) analysis. Arch Gynecol Obstet 304, 521–529 (2021). https://doi.org/10.1007/s00404-020-05952-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-020-05952-1